{"product_id":"baxter-marketing-mix","title":"Baxter International Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBaxter International’s 4P’s reveal a patient-centric product portfolio, value-based pricing across global markets, diversified hospital and distributor channels, and targeted medical-professional promotions that reinforce trust and adoption—this snapshot only hints at the strategy’s depth. Get the full, editable 4Ps Marketing Mix Analysis to unlock data-driven insights, ready-made slides, and actionable recommendations for benchmarking or strategy work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfusion Systems and Smart Pump Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBaxter’s infusion systems, led by Novum IQ and Spectrum IQ, use dose error reduction software to cut medication errors and boost patient safety in ICUs and wards.\u003c\/p\u003e\n\u003cp\u003eThese pumps enable precise fluid and drug delivery, supporting critical-care dosing where accuracy affects outcomes and length of stay.\u003c\/p\u003e\n\u003cp\u003eBy year-end 2025 Baxter completed EHR integrations across ~1,200 hospitals, trimming manual charting time and reducing data-entry errors by an estimated 30% in pilot sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSterile Intravenous Solutions and Injectable Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBaxter, a leader in the IV fluid market, makes premixed injectable drugs and standard solutions for hydration and medication delivery, supporting over 40% of US hospital IV demand in 2024 per IMS Health data.\u003c\/p\u003e\n\u003cp\u003eThe portfolio includes frozen premixed meds and specialized container systems that cut contamination and prep errors, lowering medication errors by up to 30% in acute-care studies.\u003c\/p\u003e\n\u003cp\u003eThese sterile products target emergency and ICU use where speed and sterility drive outcomes, with typical bedside administration time reduced by 20%.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Baxter is expanding its generic injectable line to capture price-sensitive hospital spend, aiming to grow injectable revenues from $1.8B in 2024 to an estimated $2.1B in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Nutrition and Parenteral Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBaxter offers comprehensive parenteral nutrition—multi-chamber bags, vitamins, and minerals—that deliver nutrients intravenously for patients unable to eat; the global PN market was $6.2B in 2024, with Baxter holding a leading share.\u003c\/p\u003e\n\u003cp\u003eThese therapies target hospital and home-care patients after surgery or with chronic illness; in 2024 Baxter reported $1.1B revenue from nutrition therapies. \u003c\/p\u003e\n\u003cp\u003eFor 2025 Baxter emphasizes personalized nutrition via digital tools that calculate precise needs, aiming to reduce complication rates and cut length-of-stay by measurable margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Surgical Hemostats and Sealants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBaxter’s Advanced Surgical Hemostats and Sealants, including Floseal and Tisseel, reduce bleeding and transfusion needs, cutting procedure time by up to 20% in some cardiovascular and spinal studies (2023–2024 hospital data).\u003c\/p\u003e\n\u003cp\u003eThese biologics are used across cardiovascular, spinal, and general surgery and, in 2025, Baxter launched ergonomic delivery formats for minimally invasive procedures to improve application speed and surgeon control.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFloseal\/Tisseel: hemostasis and tissue sealant\u003c\/li\u003e\n\u003cli\u003eClinical impact: up to 20% faster procedures\u003c\/li\u003e\n\u003cli\u003eBenefit: fewer transfusions, better outcomes\u003c\/li\u003e\n\u003cli\u003e2025: new ergonomic MIS delivery formats\u003c\/li\u003e\n\u003cli\u003eUsed in: cardiovascular, spinal, general surgery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Care Communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBaxter’s post-Hillrom portfolio delivers digital health and connected-care tools—smart beds, vitals monitors, and real-time alert systems—that link hospital units and cut response times.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Baxter is pushing AI-driven predictive alerts to prevent falls and deterioration; pilot data shows up to 22% fewer adverse events and projected ~$120M incremental service revenue by 2026.\u003c\/p\u003e\n\u003cp\u003eThe digital ecosystem aims to reduce length of stay and nurse alarm fatigue, integrating EMR feeds and IoT sensors for faster, coordinated care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmart beds + monitors: real-time alerts\u003c\/li\u003e\n\u003cli\u003eAI predictive insights: pilot -22% adverse events\u003c\/li\u003e\n\u003cli\u003eEstimated $120M incremental revenue by 2026\u003c\/li\u003e\n\u003cli\u003eEMR + IoT integration: lower LOS, less alarm fatigue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBaxter boosts care outcomes while scaling injectables to $2.1B and digital services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBaxter’s product mix—infusion pumps, IV fluids, premixed injectables, parenteral nutrition, hemostats, and connected-care devices—targets acute and home care with strong clinical impact (med error ↓30%, procedure time ↓20%, adverse events ↓22%) and 2024–25 revenues: injectables $1.8B→$2.1B (est 2025), nutrition $1.1B (2024). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfusion\u003c\/td\u003e\n\u003ctd\u003eErrors ↓30%\u003c\/td\u003e\n\u003ctd\u003e1,200 EHR sites (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInjectables\u003c\/td\u003e\n\u003ctd\u003eHospital share 40%\u003c\/td\u003e\n\u003ctd\u003e$1.8B→$2.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutrition\u003c\/td\u003e\n\u003ctd\u003eMarket $6.2B (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.1B rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical\u003c\/td\u003e\n\u003ctd\u003eTime ↓20%\u003c\/td\u003e\n\u003ctd\u003eNew MIS formats (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003eAdverse events ↓22%\u003c\/td\u003e\n\u003ctd\u003e$120M svc rev by 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Baxter International’s Product, Price, Place, and Promotion strategies—ideal for managers and consultants needing a clear breakdown of Baxter’s market positioning grounded in real practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Baxter International’s 4P marketing strategy into a concise, leadership-ready snapshot that clarifies product, price, place, and promotion choices to relieve planning friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing and Regional Distribution Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBaxter operates manufacturing sites and distribution hubs across North America, Europe, Asia, and Latin America, supporting global supply of IV solutions, renal and parenteral nutrition products.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Baxter prioritized regionalizing its supply chain, cutting freight costs an estimated 8–12% and lowering CO2 emissions from logistics by targeted 15% versus 2022 baselines.\u003c\/p\u003e\n\u003cp\u003eStrategic placement ensures high-volume items like IV solutions reach customers with lead times under 7 days in major markets, stabilizing supply despite regional demand swings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Acute Care Direct Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary access point for Baxter products is hospitals, where Baxter holds direct contracts with procurement and clinical leads and generated about 55% of 2024 revenues from institutional sales.\u003c\/p\u003e\n\u003cp\u003eSales reps work with hospital admins to tailor system integration and ensure clinicians get training and technical support for complex devices, reducing device-related incidents by an estimated 18% in pilot programs.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Baxter upgraded direct-to-hospital logistics to offer just-in-time inventory for critical supplies, cutting stockouts by 30% and lowering working capital tied to inventory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome Care and Chronic Disease Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBaxter delivers long-term nutritional support and specialty meds to patients at home via a dedicated logistics network that achieved 98% on-time delivery in 2024, serving ~150,000 home-care patients globally.\u003c\/p\u003e\n\u003cp\u003eThe company supplies infusion pumps, enteral feeding devices, and training materials, enabling clinician-supervised care outside hospitals.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Baxter increasingly integrates remote monitoring—connected pumps and telehealth—that studies show can cut readmissions by ~20% and improve adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships with Distributors and Wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBaxter extends reach to smaller clinics, nursing homes, and select international markets via third-party distributors and wholesalers, covering markets where direct presence is inefficient; in 2024 third-party channels accounted for roughly 28% of global sales (about $2.1B of $7.5B in device \u0026amp; renal product revenue).\u003c\/p\u003e\n\u003cp\u003ePartners provide local regulatory know-how and segment expertise while Baxter enforces strict quality, distribution audits, and supplier KPIs to protect product integrity and compliance across ~100 countries.\u003c\/p\u003e\n\u003cp\u003eThis multi-tiered distribution strategy increases market coverage and supports faster local rollout, lowering fixed costs and improving SKU availability in remote regions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~28% of device \u0026amp; renal sales via third parties in 2024\u003c\/li\u003e\n\u003cli\u003eDistribution footprint: ~100 countries\u003c\/li\u003e\n\u003cli\u003eRegular audits and supplier KPIs ensure compliance\u003c\/li\u003e\n\u003cli\u003eReduces fixed costs, improves local SKU availability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Procurement and E-Commerce Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBaxter has expanded digital procurement and e-commerce platforms enabling healthcare providers to manage inventory and place orders via a streamlined online interface, cutting order cycle time by about 20% versus 2020 levels.\u003c\/p\u003e\n\u003cp\u003eThese tools show real-time product availability, shipping status, and billing; by 2025 automated replenishment—using demand analytics—predicts needs with ~92% fill-rate accuracy, reducing stockouts and manual admin work.\u003c\/p\u003e\n\u003cp\u003eThe digital approach lowers Baxter’s order-processing costs (estimated 15% savings) and improves order accuracy, boosting customer retention and operational efficiency.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20% faster order cycles\u003c\/li\u003e\n\u003cli\u003e92% predicted fill-rate accuracy (2025)\u003c\/li\u003e\n\u003cli\u003e15% order-processing cost savings\u003c\/li\u003e\n\u003cli\u003eReal-time availability, shipping, billing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBaxter: 98% home-care OTD, 7‑day lead times, 30% fewer stockouts, 8–12% lower freight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBaxter uses regional hubs, direct hospital contracts, third-party distributors (~28% of device \u0026amp; renal sales in 2024), and digital procurement to ensure \u0026lt;7-day lead times in major markets, 98% home-care on-time delivery (2024), 92% predicted fill-rate (2025), and JIT logistics that cut stockouts 30% and freight costs 8–12%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eThird-party sales % (2024)\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome-care OTD (2024)\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill-rate accuracy (2025)\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockout reduction\u003c\/td\u003e\n\u003ctd\u003e30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreight cost cut\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eBaxter International 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Baxter International 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eIt covers Product, Price, Place, and Promotion with actionable insights and ready-to-use recommendations tailored to Baxter’s market position.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing the exact, fully complete document included with your order, editable and formatted for immediate application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750144291193,"sku":"baxter-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/baxter-marketing-mix.png?v=1772222638","url":"https:\/\/growthsharematrix.com\/products\/baxter-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}